Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis

Introduction: existing research on children consists primarily of phase I/II clinical trials for VEGFR-TKI. System reports of safety on the use of VEGFR-TKI in pediatrics are lacking. Aim: to investigate the safety profiles of VEGFR-TKI in pediatrics via the FDA Adverse Event Reporting System (FAERS...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Yifei, Feng, Shuo, Li, Guangyao, Zhang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291139/
https://www.ncbi.nlm.nih.gov/pubmed/37377925
http://dx.doi.org/10.3389/fphar.2023.1160117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291139/
https://www.ncbi.nlm.nih.gov/pubmed/37377925
http://dx.doi.org/10.3389/fphar.2023.1160117

Ejemplares similares